Group Nutrition and Communications Manager

Market valuation vs. Asset value: why Synlait holds greater worth for Fonterra and a2 Milk. Strategic analysis examines why Synlait's Dunsandel assets and SAMR registrations hold greater value for Fonterra and a2 Milk than as a standalone firm. Strategic analysis examines why Dunsandel's processing scale and SAMR formula registrations make the distressed processor more valuable inside a joint corporate structure. Financial and agribusiness analysts examining the trans-Tasman dairy sector argue that distressed infant formula manufacturer Synlait Milk carries significantly greater strategic and economic value as an integrated asset within Fonterra and The a2 Milk Company than it can realize operating independently. While Synlait's public equity valuation on the NZX has languished near historical lows - pressured by heavy debt service, operational losses, and customer concentration risk - its underlying industrial infrastructure represents irreplaceable processing capacity in Canterbury that would require hundreds of millions of dollars and multi-year regulatory processes to replicate organically. For The a2 Milk Company, the economic calculus centers on safeguarding high-margin infant formula revenue and eliminating supply chain friction. Synlait's flagship Dunsandel facility holds the vital State Administration for Market Regulation (SAMR) registration required to manufacture China-label infant milk formula (IMF), which historically generated nearly half of a2 Milk's total formula revenue. While a2 Milk is expanding its own Pōkeno facility in the North Island, relying on a struggling contract manufacturer introduces recurring inventory bottlenecks; acquiring direct operational control or joint ownership would permanently secure these critical China registrations and protect brand equity across key Asian retail channels. For Fonterra, participating in a transaction offers immediate capacity rationalization, regional milk pool defense, and competitive consolidation. The Dunsandel processing complex collects more than 800 million litres of milk annually from Canterbury dairy farmers and operates advanced dryers producing between 450 and 500 tonnes of high-specification powder daily. Absorbing this milk pool and processing footprint into Fonterra's manufacturing matrix would eliminate an aggressive regional competitor for raw milk supply, optimize transport logistics across the South Island, and allow the cooperative to redeploy capital from its recent $3.3 billion consumer divestment into core B2B processing scale. The structural thesis posits that Synlait's standalone discount reflects governance complexity and high financing costs rather than a lack of asset utility. Operating as an independent public entity burdened by a $NZ320 million banking syndicate debt structure and a majority 65 percent controlling stake held by Chinese state-owned Bright Dairy, Synlait faces structural overhead that erodes operating margins. In contrast, under a joint take-private framework, public listing costs and corporate duplication would be eliminated, while a2 Milk secures specialized infant formula production and Fonterra integrates bulk powder drying capacity. The market dynamics surrounding Synlait illustrate how dairy processing overcapacity and tightening regulatory access are accelerating structural consolidation across New Zealand. Even as Synlait management publicly rebuffs buyout speculation to focus on internal operational turnarounds, the industrial synergy between Dunsandel's hardware and the balance sheets of Fonterra and a2 Milk remains compelling. As the global dairy industry prioritizes vertical integration, balance sheet resilience, and high-margin nutritional formulations, specialized processing assets will increasingly gravitate toward well-capitalized industry leaders. You may be interested in. Legal Notice Related notes.

a2 Milk annual profit falls 44 percent as plant deals cloud a stronger underlying result. August 17, 2026 The a2 Milk Company reported an annual net profit of $113.6 million on Monday, down 44 percent on the $202.9 million it made a year earlier, in a result the company said was distorted by the sale of one New Zealand processing plant and the purchase of another. Revenue for the year to 30 June rose 12.4 percent to about $1.97 billion, the highest in the company's history and the first time it has come within touching distance of the $2 billion mark that has been its stated ambition for several years. Strip out the one-off items and the picture is a good deal brighter than the headline number suggests. Underlying earnings before interest, tax, depreciation and amortisation rose 5.4 percent to $307.6 million, and underlying net profit rose 7 percent to $235.8 million. Net profit from continuing operations came in at $207.5 million, against $220.3 million the year before. Chief executive David Bortolussi said the bottom line reflected the pluses and minuses of two large transactions that landed in the same financial year. a2 Milk sold its majority stake in Mataura Valley Milk near Gore early in the year, booking a net loss of $96 million on the way out, and completed the purchase of a large plant at Pōkeno, south of Auckland, which it now trades as a2 Pōkeno and expects to turn profitable in the current year. "So I appreciate it's a complicated result to explain this year, but the underlying fundamentals and underlying results of the business are still very strong," Bortolussi told reporters, in comments reported by RNZ. Shareholders will collect ordinary dividends of 21 cents a share for the year, up from 20 cents. That sits on top of the special dividend of 41.36 cents a share, worth roughly $300 million, that the company declared in late June after Chinese regulators approved the transfer of two infant formula registrations to a2 branded products, and paid out in July. The softer parts of the result were where the market had been told to expect them. Sales of China label infant formula, the highest margin part of the business, fell during the year after supply problems in the fourth quarter left shelves short and pushed some Chinese shoppers towards rival brands or towards a2's own English label tins. The company told the market in July that those problems had largely been fixed and stock levels were back near target. Growth in English label formula, in other nutritional products and in liquid milk in Australia and New Zealand more than covered the gap. Revenue in the United States, a market a2 Milk has been grinding away at for years, rose by close to 29 percent and the American business broke even in the second half. Bortolussi framed the Pōkeno purchase as the fix for the supply weakness that hurt the company this year. "The successful acquisition and transformation of a2 Pōkeno is a significant step in strengthening our supply chain and enabling growth with the launch of two new China label infant milk formula products planned for the first half of FY27," he said. On the year ahead, he said revenue and underlying earnings were both expected to grow, "supported by increased contribution from product innovation and new markets, continued momentum in Other Nutritionals and Liquid Milk, and a2 Pōkeno profitability improvement". The company warned that the recovery in China would be gradual and that growth would be weighted heavily to the second half of the year, and it listed a long run of risks around that forecast, from competitive intensity and cross border trade to currency movements, the farmgate milk price and the conflict in the Middle East. Investors took the cautious tone badly. a2 Milk shares fell as low as $7.39 during Monday morning, more than 10 percent below Friday's close of $8.23, before clawing back some ground to trade around $7.89 by mid afternoon, still down about 4 percent on the day. Sitting behind the numbers was a second story the company would not discuss. Reports published on Monday, originating with The Australian, suggested a2 Milk and Fonterra were working together on a plan to take Synlait Milk private. Synlait, which has had several rough years, responded with a statement to the New Zealand Exchange saying it was "not involved in any discussions with The a2 Milk Company or Fonterra regarding the matters referred to in those reports", according to RNZ. Fonterra and a2 Milk both declined to comment on market speculation. Asked about it at the results briefing, Bortolussi said only that "we have a great relationship with both companies, with Fonterra and Synlait", and pointed instead at the plant his company has just bought. "Also I would add that our acquisition of the a2 Pōkeno facility in the North Island of New Zealand and the hundreds of millions of dollars that we're investing in that facility and its capital upgrade program is indicative of our strategy going forward," he said. The two companies are already tied together. a2 Milk owns just under 20 percent of Synlait, and Synlait's Dunsandel plant in Canterbury holds the Chinese registration that allows a2's China label formula to be made and sold there. Synlait reported a loss of $80.6 million for the six months to late January with debt of $472.1 million, and last year sold its North Island operations for $307 million to take pressure off its balance sheet. For a company that sells almost all of its product offshore and makes most of it here, the year's two plant deals matter more than the wobble in the profit line. a2 Milk has swapped a Southland plant it did not need for a bigger northern one it says it does, and it now owns the capacity to make the formula that earns it the most money. Whether that removes its dependence on Synlait, or simply makes the case for buying the rest of it, is the question the market will spend the next year answering. The full result is available on the company's results and reports page. What do you make of a2 Milk's year, and should New Zealand's biggest formula exporter own more of its own processing? Leave a comment below and tell News Wire what you think.

New Zealand's a2 Milk full-year profit falls 44% on weaker China-label IMF sales. By Reuters Reuters Updated August 16, 2026 2:48 PM Gift Article Aug 17 (Reuters) - New Zealand's a2 Milk reported a 44% drop in its full-year profit on Monday as customers switched to other brands after supply chain disruptions left its key China-label infant milk formula (IMF) product out of stock. Revenue from China-label IMF sales declined by 14% to NZ$544.3 million ($320.59 million) in the year ended June 30, as strong third-quarter demand, production backlog, and higher freight costs disrupted supply and caused product shortage in the June quarter. The disruption "materially impacted in-market product availability during 4Q26 and necessitated a large proportion of existing users to switch to alternative brands as they ran out of pantry stock mainly in June," the company said. However, it added that stock levels had significantly improved and it was focusing on "regaining past users and accelerating new user recruitment". As a result, the dairy producer's net profit attributable fell to NZ$113.6 million for the year, missing the Visible Alpha consensus estimate of NZ$121 million, and below last year's NZ$202.9 million. On an underlying basis, a2 Milk reported full-year profit of NZ$235.8 million, 7% higher than last year. Revenue from its largest market, China & other Asia, rose 11.2% in the year to NZ$1.45 billion, led by higher sales of English-label IMF products. The company declared a final dividend of 9.5 New Zealand cents per share, down from the 11.5 cents a year earlier ($1 = 1.6978 New Zealand dollars) (Reporting by Shruti Agarwal and Anjali Singh in Bengaluru; Editing by Edmund Klamann and Chizu Nomiyama) This story was originally published August 16, 2026 at 2:05 PM.